4th Annual eMarketing Summit Europe 2009

eyeforpharmaApril 27-28, 2009, Munich, Germany.
eyeforpharma's leading eMarketing Summit returns for it's forth successful year with a new format and new concepts for 2009, you'll hear from the most experienced and innovative eMarketing experts and enjoy an interactive hands-on learning experience.

Join the 2009 Summit and get fresh perspectives on how to revitalise your online campaigns by introducing better measurement, coordination and execution strategies into your Marketing Mix.

At no other time and in no other place can you find such a high concentration of know-how and innovative ideas in one venue!

Some of the hot topics to be adressed in the Summit:

  • Changing role of eMarketing teams: profile, training and development: Get the answers to such questions as: What is the profile of people responsible for your on-line strategies? How many people should be involved and how to train and develop them?
  • Branding and eMarketing: The move from product strategy to implementation: Learn new ways to better align your brand plan and digital tactics to facilitate cohesive relationships between your customers and brands.
  • Physician’s communities and physicians search behaviour: Understand how physicians recently use and feel about on-line medical information in order to identify their unmet needs for tools and services.
  • New tools for better targeting. What Web 2.0 can offer to build long-term relationships?: Find the answers to essential questions about how to use Web 2.0 to your benefit and form a better overview of its potential.
  • Search Engine Marketing: How to improve its performance? Hear specific examples on how companies implement SEM projects to meet your client’s needs.

For further information, please visit:
http://www.eyeforpharma.com/emarketing/

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...